X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (23974) 23974
Book Chapter (197) 197
Dissertation (159) 159
Magazine Article (71) 71
Web Resource (30) 30
Book / eBook (26) 26
Newsletter (25) 25
Publication (16) 16
Conference Proceeding (11) 11
Reference (9) 9
Streaming Video (6) 6
Newspaper Article (3) 3
Book Review (2) 2
Trade Publication Article (2) 2
Government Document (1) 1
Journal / eJournal (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14627) 14627
dyslipidemia (13833) 13833
male (10022) 10022
female (9181) 9181
risk factors (7699) 7699
middle aged (7030) 7030
adult (5547) 5547
cholesterol (5127) 5127
aged (4689) 4689
obesity (4303) 4303
hypertension (3973) 3973
lipids (3805) 3805
metabolic syndrome (3652) 3652
diabetes (3631) 3631
dyslipidemias - drug therapy (3446) 3446
dyslipidemias - blood (3120) 3120
prevalence (3095) 3095
atherosclerosis (2997) 2997
dyslipidemias - epidemiology (2927) 2927
insulin resistance (2926) 2926
animals (2898) 2898
diabetes mellitus (2860) 2860
cardiovascular disease (2835) 2835
cardiovascular diseases (2712) 2712
dyslipidemias - complications (2621) 2621
risk (2601) 2601
dyslipidemias (2365) 2365
body mass index (2356) 2356
cardiac & cardiovascular systems (2354) 2354
endocrinology & metabolism (2298) 2298
insulin-resistance (2257) 2257
lipids - blood (2239) 2239
triglycerides (2230) 2230
cardiovascular-disease (2157) 2157
triglycerides - blood (2129) 2129
research (2125) 2125
lipoproteins (2111) 2111
coronary-heart-disease (2095) 2095
cholesterol, ldl - blood (2015) 2015
statins (1914) 1914
pharmacology & pharmacy (1892) 1892
disease (1874) 1874
cross-sectional studies (1853) 1853
metabolism (1852) 1852
cholesterol, hdl - blood (1805) 1805
mortality (1780) 1780
adolescent (1745) 1745
inflammation (1735) 1735
health aspects (1707) 1707
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1697) 1697
treatment outcome (1683) 1683
medicine, general & internal (1633) 1633
blood pressure (1606) 1606
risk-factors (1592) 1592
glucose (1553) 1553
peripheral vascular disease (1532) 1532
analysis (1497) 1497
prevention (1488) 1488
insulin (1481) 1481
biomarkers - blood (1480) 1480
cardiovascular diseases - prevention & control (1459) 1459
care and treatment (1432) 1432
young adult (1425) 1425
cholesterol - blood (1423) 1423
nutrition & dietetics (1414) 1414
hypolipidemic agents - therapeutic use (1409) 1409
type 2 diabetes (1407) 1407
hypertension - epidemiology (1386) 1386
diet (1367) 1367
association (1350) 1350
biochemistry & molecular biology (1349) 1349
cardiovascular diseases - etiology (1343) 1343
medicine (1338) 1338
low density lipoproteins (1325) 1325
oxidative stress (1279) 1279
cardiovascular diseases - epidemiology (1259) 1259
dyslipidemias - metabolism (1233) 1233
mice (1227) 1227
aged, 80 and over (1201) 1201
dyslipidemias - diagnosis (1151) 1151
risk assessment (1136) 1136
metabolic disorders (1134) 1134
studies (1125) 1125
cardiovascular (1119) 1119
dyslipidemias - etiology (1116) 1116
physiological aspects (1114) 1114
hypercholesterolemia (1110) 1110
child (1101) 1101
comorbidity (1081) 1081
population (1079) 1079
retrospective studies (1078) 1078
cardiovascular risk (1064) 1064
lipid metabolism (1062) 1062
rats (1053) 1053
liver (1050) 1050
density-lipoprotein cholesterol (1022) 1022
blood-pressure (984) 984
time factors (965) 965
abridged index medicus (961) 961
research article (960) 960
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (16) 16
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Gerstein Science - Stacks (3) 3
Scarborough Hospital - Online (2) 2
Mt Sinai Hospital - Online (1) 1
St. Michael's Hospital - Online (1) 1
St. Michael's Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22496) 22496
Spanish (741) 741
Portuguese (643) 643
Russian (322) 322
French (302) 302
Japanese (271) 271
Chinese (207) 207
German (159) 159
Czech (123) 123
Polish (98) 98
Korean (88) 88
Italian (66) 66
Hungarian (32) 32
Turkish (26) 26
Romanian (18) 18
Slovak (14) 14
Ukrainian (14) 14
Persian (13) 13
Norwegian (12) 12
Lithuanian (11) 11
Croatian (8) 8
Serbian (7) 7
Swedish (6) 6
Danish (4) 4
Dutch (4) 4
Finnish (4) 4
Indonesian (4) 4
Slovenian (4) 4
Arabic (3) 3
Hebrew (3) 3
Breton (2) 2
Icelandic (2) 2
Belarusian (1) 1
Bosnian (1) 1
Bulgarian (1) 1
Galician (1) 1
Greek (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Scientific reports, ISSN 2045-2322, 12/2020, Volume 10, Issue 1, pp. 1 - 1
An amendment to this paper has been published and can be accessed via a link at the top of the paper. 
Dyslipidemia
Journal Article
BMC infectious diseases, ISSN 1471-2334, 2017, Volume 17, Issue 1, pp. 551 - 17
Background: Aim of this review is to focus the attention on people living with HIV infection at risk of developing a cardiovascular event. What is or what... 
HIV | Cardiovascular risk | Dyslipidemia | Ezetimibe | Lipodystrophy | Fibrates | Omega 3 fatty acids ART | Statins | INFECTIOUS DISEASES | EZETIMIBE PLUS STATIN | HORMONE-RELEASING FACTOR | NAIVE HIV-1-INFECTED PATIENTS | BOOSTED PROTEASE INHIBITOR | DENSITY-LIPOPROTEIN CHOLESTEROL | REVERSE-TRANSCRIPTASE INHIBITORS | MAINTENANCE ANTIRETROVIRAL THERAPY | DOUBLE-BLIND | INFECTED PATIENTS | CORONARY-HEART-DISEASE | Cardiovascular Diseases - etiology | Lipodystrophy - prevention & control | Dyslipidemias - complications | Anti-HIV Agents - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Risk Factors | Lipids | Pyrazines - therapeutic use | Growth Hormone-Releasing Hormone - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Dyslipidemias - chemically induced | HIV Infections - complications | Pyrazines - adverse effects | Anti-HIV Agents - therapeutic use | Dyslipidemias - prevention & control | Growth Hormone-Releasing Hormone - adverse effects | HIV Infections - drug therapy | Lipodystrophy - chemically induced | Cardiovascular Diseases - chemically induced | Growth Hormone-Releasing Hormone - analogs & derivatives | Cholesterol - therapeutic use | Prevention | Highly active antiretroviral therapy | Care and treatment | Exercise | Dyslipidemias | Dosage and administration | Diagnosis | Research | Cardiovascular diseases | Health aspects | Omega-3 fatty acids | Drugs | Intervention | Therapy | Physical activity | Toxicity | Risk factors | Guidelines | Antiretroviral agents | Intestine | Human immunodeficiency virus--HIV | Intestinal absorption | Integrase | Antiretroviral drugs | Antiviral agents | Drug addiction | Kidneys | Immunomodulation | Mortality | Health risks | Risk reduction | Proteinase inhibitors | Inflammation | Risk taking | Patients | Fatty acids | Antiretroviral therapy | Cholesterol | Studies | Hypercholesterolemia | Protease inhibitors | Diet | Hypertriglyceridemia | Weight reduction | Health risk assessment | Kidney transplantation | Smoking
Journal Article
Atherosclerosis, ISSN 0021-9150, 2015, Volume 239, Issue 2, pp. 483 - 495
Abstract Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality for patients with type 2 diabetes, despite recent significant... 
Cardiovascular | Type 2 diabetes | CVD | Fatty liver | Dyslipidemia | β-oxidation | Triglycerides | De novo lipogenesis (DNL) | CARDIAC & CARDIOVASCULAR SYSTEMS | DE-NOVO LIPOGENESIS | FATTY LIVER-DISEASE | B-CONTAINING LIPOPROTEINS | LOW-DENSITY-LIPOPROTEIN | TRIGLYCERIDE-RICH LIPOPROTEINS | STEAROYL-COA DESATURASE | beta-oxidation | HEPATIC INSULIN-RESISTANCE | PERIPHERAL VASCULAR DISEASE | CORONARY-HEART-DISEASE | GROWTH-FACTOR 21 | APOLIPOPROTEIN-C-III | Prevalence | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Intestines - metabolism | Liver - physiopathology | Diabetes Mellitus, Type 2 - epidemiology | Dyslipidemias - blood | Cardiovascular Diseases - blood | Cardiovascular Diseases - epidemiology | Dyslipidemias - diagnosis | Cardiovascular Diseases - physiopathology | Dyslipidemias - drug therapy | Risk Assessment | Liver - metabolism | Risk Factors | Biomarkers - blood | Lipoproteins - blood | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - blood | Animals | Diabetes Mellitus, Type 2 - physiopathology | Dyslipidemias - epidemiology | Lipid Metabolism - drug effects | Triglycerides - blood | Hypolipidemic Agents - therapeutic use | Intestines - physiopathology | Blood Glucose - metabolism | Dyslipidemias - physiopathology | Blood lipids | Low density lipoproteins | Mortality | HEPATIC | ISCHEMIC-HEART-DISEASE | Peripheral Vascular Disease | Kardiologi | Cardiac and Cardiovascular Systems | NONALCOHOLIC FATTY LIVER | INSULIN-RESISTANCE | CORONARY-ARTERY-DISEASE
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 2016, Volume 11, Issue 4, p. e0153497
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of diseases from simple steatosis to non-alcoholic steatohepatitis, with approximately 20% risk of... 
DIAGNOSIS | AMERICAN ASSOCIATION | RECOMMENDATIONS | MULTIDISCIPLINARY SCIENCES | CONTROLLED ATTENUATION PARAMETER | MARKERS | STEATOHEPATITIS | MICRORNAS | HEPATIC STEATOSIS | EXPRESSION | PCR | Dyslipidemias - genetics | Up-Regulation | Liver - pathology | Cross-Sectional Studies | Dyslipidemias - complications | Non-alcoholic Fatty Liver Disease - genetics | Humans | Middle Aged | Male | Non-alcoholic Fatty Liver Disease - complications | Young Adult | Caenorhabditis elegans | Non-alcoholic Fatty Liver Disease - blood | Dyslipidemias - blood | Animals | Non-alcoholic Fatty Liver Disease - diagnosis | Adult | Female | MicroRNAs - blood | MicroRNAs - genetics | Dyslipidemias - diagnosis | Complications and side effects | MicroRNA | Fatty liver | Dyslipidemias | Physiological aspects | Genetic aspects | Research | Risk factors | Biotechnology | Correlation | Nuclear magnetic resonance--NMR | Transplants & implants | Liver | Dyslipidemia | Liver cancer | Hepatitis | Ultrasonic imaging | miRNA | Obesity | Liver diseases | Medical imaging | Feasibility studies | Inflammation | Metabolism | Gene expression | Patients | Low density lipoprotein | Cholesterol | Lipoproteins (very low density) | Steatosis | Serum levels | Cirrhosis | Weight control | Biopsy | MicroRNAs | Fibrosis | Biomarkers | Diagnostic systems | Diabetes | Methods | Nuclear magnetic resonance | NMR
Journal Article